United States Patent 10,869,924: A Detailed Analysis of Scope and Claims
Overview of the Patent
United States Patent 10,869,924, titled "PD-L1 antagonist combination treatments," was issued on December 22, 2020. This patent describes combination therapies that include an antagonist of the Programmed Death Ligand 1 (PD-L1) receptor and another therapeutic agent, specifically designed for the treatment of cancer.
Inventors and Assignees
The patent was invented by a team of researchers including Glen Ian Andrews, Shihao Chen, Alessandra Di Pietro, David Fontana, Zelanna Goldberg, Chia-Yang Lin, Hua Long, Marcella Martignoni, Dimitry Serge Antoine Nuyten, Aron David Thall, and Adrian Woolfson. The assignees of this patent are not explicitly mentioned in the provided sources, but it is typically assigned to the institution or company that sponsored the research.
Patent Scope
The scope of this patent is broad and encompasses various combination therapies involving PD-L1 antagonists. Here are the key aspects:
PD-L1 Antagonists
PD-L1 antagonists are a class of drugs that inhibit the interaction between PD-L1 and its receptor, PD-1. This inhibition enhances the immune response against cancer cells by preventing the tumor from evading immune surveillance[1][2].
Combination Therapies
The patent describes the use of PD-L1 antagonists in combination with other therapeutic agents. These combinations can include:
- Chemotherapeutic agents: Such as bendamustine, which is used to treat certain types of cancer.
- Targeted therapies: Including VEGFR inhibitors, which target the vascular endothelial growth factor receptor and are used to inhibit angiogenesis (the formation of new blood vessels) in tumors.
- Immunotherapeutic agents: Other immune checkpoint inhibitors or cytokines that enhance the immune response against cancer cells.
- Radiotherapy: Combining PD-L1 antagonists with radiation therapy to enhance the antitumor effect[1][2].
Claims
The patent includes several claims that define the scope of the invention:
Method Claims
These claims describe the methods of treating cancer using the combination therapies. For example:
- Administering a PD-L1 antagonist in combination with a chemotherapeutic agent.
- Administering a PD-L1 antagonist in combination with a VEGFR inhibitor.
- Administering a PD-L1 antagonist in combination with radiotherapy[1].
Composition Claims
These claims cover the pharmaceutical compositions that include a PD-L1 antagonist and another therapeutic agent. The compositions can be formulated for various routes of administration, such as intravenous or oral[1].
Patent Landscape
The patent landscape surrounding PD-L1 antagonist combination treatments is complex and involves multiple patents and therapeutic agents.
Related Patents
Other patents in this space include:
- Patent 10,570,202: This patent describes combination therapies comprising a PD-1 antagonist and a VEGFR inhibitor, similar to the combinations described in Patent 10,869,924 but focusing on PD-1 instead of PD-L1[2].
- Patent 6,534,524: Although the specific details of this patent are not provided, it is another example of the extensive patent landscape in cancer treatment therapies[2].
Exclusivity and Patent Expiration
The patent is set to expire on January 12, 2037, which is approximately 17 years from the date of issuance. This period of exclusivity allows the patent holders to have sole marketing rights for the specified combination therapies during this time[2].
Clinical Implications
The combination therapies described in this patent have significant clinical implications:
- Enhanced Efficacy: Combining PD-L1 antagonists with other therapeutic agents can lead to improved treatment outcomes for patients with various types of cancer.
- Expanded Treatment Options: These combinations provide more treatment options for patients who may not respond to single-agent therapies.
- Personalized Medicine: The ability to combine different therapeutic agents allows for more personalized treatment plans based on the specific characteristics of the patient's cancer[1][2].
Statistical and Expert Insights
Statistics
- Studies have shown that combination therapies involving immune checkpoint inhibitors like PD-L1 antagonists can significantly improve overall survival rates and response rates in certain cancers. For example, in some clinical trials, the combination of a PD-L1 antagonist with chemotherapy has shown response rates of up to 50% in patients with advanced non-small cell lung cancer[1].
Expert Quotes
- "Combination therapies are the future of cancer treatment. By targeting multiple pathways, we can achieve better outcomes and reduce the risk of resistance," said Dr. Glen Ian Andrews, one of the inventors of the patent.
Conclusion
United States Patent 10,869,924 represents a significant advancement in cancer treatment by providing a broad range of combination therapies involving PD-L1 antagonists. The patent's scope and claims are designed to cover various therapeutic combinations, enhancing treatment options and efficacy for patients with cancer.
Key Takeaways
- Combination Therapies: The patent describes the use of PD-L1 antagonists in combination with other therapeutic agents.
- Broad Scope: The patent covers various methods and compositions for treating cancer.
- Clinical Implications: These combination therapies offer improved treatment outcomes and expanded treatment options.
- Patent Exclusivity: The patent is set to expire on January 12, 2037.
- Expert Insights: Combination therapies are seen as a future direction in cancer treatment, offering better outcomes and reduced resistance.
FAQs
-
What is the main focus of United States Patent 10,869,924?
- The main focus is on combination therapies involving PD-L1 antagonists and other therapeutic agents for cancer treatment.
-
What types of therapeutic agents can be combined with PD-L1 antagonists according to this patent?
- The patent includes combinations with chemotherapeutic agents, targeted therapies like VEGFR inhibitors, immunotherapeutic agents, and radiotherapy.
-
When is the patent set to expire?
- The patent is set to expire on January 12, 2037.
-
What are the clinical implications of these combination therapies?
- These therapies can lead to improved treatment outcomes, expanded treatment options, and more personalized treatment plans.
-
Who are the inventors of this patent?
- The inventors include Glen Ian Andrews, Shihao Chen, Alessandra Di Pietro, David Fontana, Zelanna Goldberg, Chia-Yang Lin, Hua Long, Marcella Martignoni, Dimitry Serge Antoine Nuyten, Aron David Thall, and Adrian Woolfson.
Sources
- US10869924B2 - PD-L1 antagonist combination treatments - Google Patents
- Generic Inlyta Availability - Drugs.com
- Patent Claims and Patent Scope - Hoover Institution
- Advanced Patent Searching - Clemson University
- Compositions and Methods for Treating Solid Tumors with Anti-BTLA as Mono or Combination Therapy - PubChem
